Casdin Capital’s bluebird bio BLUE Stock Holding History

Casdin Capital’s Portfolio BLUE Stock Details BLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-1,544	Closed	-$1.28M	–	29
2015 Q4	$1.28M	Buy	+1,544	New	+$1.54M	1.13%	23

Other funds holding BLUE

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Casdin Capital's BLUE Position: Q1 2021 in Review

Casdin Capital sold out of bluebird bio (BLUE) in Q1 2021, closing a stake of 70,638 shares — an estimated $39.6M sold.

Casdin Capital first reported a position in BLUE in Q4 2015 and held it in 21 quarters. The position peaked at $85.1M in Q4 2019. 229 funds tracked by Wall St. Rank hold BLUE as of Q1 2021.

Casdin Capital reported no remaining bluebird bio position as of Q1 2021 after selling out during the quarter.
Casdin Capital sold 70,638 bluebird bio shares in Q1 2021, an estimated $39.6M.
Casdin Capital first reported a position in bluebird bio in Q4 2015 and held it in 21 quarters.
Casdin Capital's bluebird bio position peaked at $85.1M in Q4 2019.
229 funds tracked by Wall St. Rank held bluebird bio as of Q1 2021.

Based on Casdin Capital's 13F filing for Q1 2021, filed 17 May 2021.